Human organoid systems recapitulate in vivo organ architecture, yet fail to capture complex pathologies such as inflammation and fibrosis. Here we developed multi-cellular human liver organoids (HLO) from 11 different healthy and diseased PSC lines that display essential features of steatohepatitis. Single-cell-level analysis revealed steatohepatitis organoids exhibited persistent hepatic steatosis, followed by progressive activation of pro-inflammatory and fibrotic lineages. Interestingly, expression of the steatohepatitis phenotype correlates with the presence of clinically significant GWAS factors: PNPLA3, GCKR and TM6SF2. We developed an organoid-level readout with atomic force microscopy, and demonstrated that organoid stiffening reflects the fibrosis severity. Furthermore, organoid model of an iatrogenic parental nutrition associated liver disease (PNALD) identified obeticholic acid as effective in preventing pathology progression, suggesting the potential repurposing for PNALD. The presented key methodology and preliminary results offer a new method for studying human precision for inflammation and fibrosis, facilitating the discovery of effective treatments.
Molecular Biology
Cell Biology
Medicine
Cancer Research
Clinical Research
Genetics
Biology
Biotechnology
Cell Line Development
Diagnostics
Assay Development
Stem Cell Technologies
Developmental Biology
Cell Culture
Pharmacology
North America56%
Europe15%
Asia12%
Africa9%
South America5%
Oceania3%
Website Visitors91%
Client/Sponsor Promotions4%
Email Promotions1%
Social Media Promotions1%
WAVE Newsletter Promotion1%
Other3%
Student37%
Research Scientist22%
Post Doc9%
Educator/Faculty8%
Medical Doctor/Specialist7%
Scientist4%
Executive4%
Marketing/Sales2%
Clinical Laboratory Scientist2%
Biologist2%
Lab Management2%
Facility/Department Manager2%
Academic Institution27%
Medical School14%
Research Institute12%
Hospital10%
Medical Center6%
Biotech Company6%
Government4%
Clinical Laboratory4%
Life Science Company3%
Non-Profit Organization3%
Association2%
Pharmaceutical Company1%
Ambulatory Care1%
Health Plan/hmo1%
Other4%